Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H5-VLP + GLA-AF
- Development stage
- Phase 1
- Lead developer
- Access to Advanced Health Institute
- Modality
- Vaccines & Immunotherapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
H5-VLP + GLA-AF is a pandemic influenza vaccine candidate developed by the Access to Advanced Health Institute (AAHI). It consists of recombinant virus-like particles (VLPs) representing the hemagglutinin (HA) of the H5N1 influenza A virus, formulated with GLA-AF, a synthetic Toll-like receptor 4 (TLR4) agonist adjuvant in an aqueous formulation. The VLPs mimic the structure of the virus but lack genetic material, making them non-infectious while presenting the HA antigen in a native-like conformation to the immune system. The GLA-AF adjuvant enhances the magnitude and breadth of the immune response, particularly Th1-biased cellular immunity and high-titer neutralizing antibodies. It is primarily indicated for the prevention of H5N1 avian influenza infection and is being evaluated for its potential to provide broad protection in a pandemic setting.
- Other names
- H5N1 VLP vaccineH-5N1 VLP vaccineH 5N1 VLP vaccineAAHI-H5N1 vaccineAAHI-H-5N1 vaccineAAHI-H 5N1 vaccineH5-VLP + GLA-AF Pandemic Influenza Vaccine
02
Targets
TLR4 (Toll-like receptor 4)HA (Hemagglutinin)
Beyond the preview
Go deeper on H5-VLP + GLA-AF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H5-VLP + GLA-AF.